Lupin Pharmaceuticals has submitted a new drug application for its etanercept biosimilar, YLB113, in Japan, the company announced today.
Lupin Pharmaceuticals has submitted a new drug application for its etanercept biosimilar, YLB113, in Japan, the company announced today. The application for marketing authorization for the drug for the indications of adult rheumatoid arthritis (RA) and juvenile idiopathic arthritis was filed in March 2018.
“The application for etanercept biosimilar is a significant milestone for Lupin as we build our biosimilars pipeline. With the application now filed, we are preparing to launch an affordable and high-quality biosimilar for consumers in Japan. This is an encouraging outcome as we make a strategic shift across Lupin to higher complexity products,” said Nilesh Gupta, managing director of Lupin.
In February of this year, Lupin and its partner, Yoshindo Inc, announced the successful completion of a global phase 3 clinical trial of the proposed etanercept biosimilar. The multinational, randomized, double-blind, 52-week controlled trial of the product was conducted in more than 500 patients with RA and compared the safety and efficacy of the proposed biosimilar with that of the reference product, Enbrel.
The study met its primary end point of equivalent improvement in RA, measured by American College of Rheumatology (ACR) criteria for 20% improvement (ACR20), at week 24, and the safety and immunogenicity of YLB113 were also similar to those of the reference Enbrel. Secondary end points for the trial included ACR50 and ACR70 (50% and 70% improvement, respectively) at weeks 4, 8, 12, and 24, as well as improvement in disease activity score using a count of 28 tender and swollen joints.
Also this year, Lupin announced that it plans to file for regulatory approval of the biosimilar etanercept in the first quarter of 2019 in Europe and in the third quarter of the 2020 fiscal year in the United States. Looking farther in Lupin’s biosimilar pipeline, a proposed ranibizumab product is currently in phase 1 clinical trials, while pegfilgrastim, filgrastim, denosumab, pertuzumab, and afliberept are all in early stages of development.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).